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decade ago, the schizophrenia prevention
movement was launched with great expectations.At that
time,a handful of treatment studies began,founded more
on enthusiasm,intuition,and indirect findings than on a
solid base of evidence.Today,though still in its infancy,
the field thrives.Early intervention programs have dra-
matically proliferated around the world, and the data,
though still sparse, are nonetheless quite encouraging.
The target of these studies is the schizophrenia “pro-
drome,”which refers to the phase of illness that precedes
the onset of psychosis. Treatment, to date, has been
largely pharmacological,although at least one major psy-
chotherapy trial has now begun in the United Kingdom.
1
In this paper,we will review the treatment findings cur-
rently available that address the following basic issues:
(i) what should be treated;(ii) when should treatment be
initiated;and (iii) how long should treatment last.First,
we begin with why: why begin treatment prior to psy-
chosis,the stage of illness that defines schizophrenia?
Why treat the prodromal phase 
of schizophrenia?
Initially,the prevention movement gained early momentum
from the convergence of two,very separate,research tradi-
tions.The first of these established the neurodevelopmen-
tal view of schizophrenia,now widely accepted throughout
the field.This model provides the logic of early interven-
tion.The second tradition is far more empirical,and is based
on increasing evidence that early treatment, initiated as
close after onset of psychosis as possible, appears to
improve outcome.It thus follows from these findings that
treatment started before onset might be better still.
39
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Early intervention and prevention in schizophrenia is just
over 10 years old. The assumption guiding this field is that
intervention is likely to be most effective if it begins
before psychosis sets in, ie, during the prodromal phase.
Although a substantial number of prodromal treatment
programs have been initiated around the world, three
early programs have generated most of the intervention
findings to date: Personal Assessment and Crisis Evaluation
(PACE) in Australia, and the Prevention through Risk
Identification, Management, and Education (PRIME) and
Recognition and Prevention (RAP) programs in the USA.
The data suggest that early intervention leads to a reduc-
tion in prodromal symptoms and clinical distress. However,
prevention of psychosis remains an unresolved question.
Other issues include defining who should be treated, with
what, and when. In addition, treatment targets associated
with functional disability, such as early prodromal nega-
tive symptoms and risk factors, continue to emerge. Newly
identified targets, in turn, suggest the need for a variety
of novel interventions and treatment strategies.  
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The currently accepted view of schizophrenia holds that
it is a gradually unfolding illness,one that has its roots in
prenatal development.Though the evidence is indirect,it
is believed that a genetic error of some kind (most likely
in interaction with other biological and environmental
factors) leads to subtle abnormalities in the evolving
brain.The resulting pathophysiology is not,in itself,schiz-
ophrenia,but rather a susceptibility or vulnerability to the
disorder.Subtle vulnerability indicators can be detected
throughout late childhood and early adolescence (eg,cog-
nitive impairments,social difficulties),but the underlying
disturbance begins to fulminate toward midadolescence,
when clinical warning signs (ie,attenuated positive symp-
toms) become increasingly apparent.A number of mod-
els,differing from each other mainly in details,have been
derived from this basic set of assumptions.
2-10
The neurodevelopmental model is widely supported by
both genetic high-risk prospective and birth cohort fol-
low-back studies.In particular,genetic high-risk studies
have implicated early cognitive and social skill deficits in
young at-risk offsprings of schizophrenic parents who
later become ill.
11-14 Follow-back studies, such as the
British
15,16 and Finnish birth cohorts,
17 and the large pop-
ulation Swedish conscripts
18,19 and Israeli army studies,
7
have consistently reported a diversity of cognitive,social,
and other developmental precursors to schizophrenia.
The application of the neurodevelopmental view to pre-
vention is threefold:first,this model depicts the clinical
illness as a long-term,developmental process.As a result,
intervention is viewed as being possible well before psy-
chosis sets in, and thus, as having the potential to stop
continued progression to illness.Second,the proposed
presence of a detectable,biological vulnerability provides
the mechanism for early detection.In order to begin pre-
ventive treatment prior to illness onset,there must be a
way to identify who is in need of intervention.Prodromal
vulnerability indicators provide the means to identify
those individuals who are at risk for illness.It should be
noted that this represents a major advance,since risk has
traditionally been a group construct,not definable on an
individual level.Third,the course of the prodromal phase
of illness and the emergence of deficits point to type of
treatment,in indicating the actual targets for treatment
(eg, cognition, depression, social anxiety) and when it
should begin (early versus late prodrome).
Early treatment findings and the duration of untreated
psychosis 
Clinical researchers have long noted that many patients
with psychosis appear to experience a prodromal phase
characterized by alterations in perception and changes in
behavior.
20-22 As early as 1927, Sullivan observed that
“The great number of our patients have shown for years
before the break, clear signs of coming trouble …”
23
Similarly, Meares
22 maintained,“What is needed is not
the early diagnosis of schizophrenia,but the diagnosis of
prepsychotic schizophrenia.” Despite the widespread
clinical recognition of the prodrome,little attention had
been directed at this phase of illness until recently,most
likely because prevention was not possible.Recent inter-
est has developed and increased with the availability of
potential treatment tools:antipsychotic (AP) medication.
The importance of early treatment was first suggested by
Wyatt et al,
24-26 who provided indirect evidence suggesting
that the earlier medication was initiated after onset of
schizophrenia, the better the outcome, thus suggesting
that psychosis itself is toxic to the brain.The association
of the duration of untreated psychosis (or DUP) with
prognosis has since been supported by a substantial num-
ber of studies
27,28 (although there are contradictory find-
ings
29-31) and has often been cited to suggest that treatment
initiated before onset is likely to lead to the best out-
come.
32,33 The introduction of second-generation APs
(SGAPs) with an apparently reduced side-effect profile
contributed significantly to the feasibility and ethicality
of such early treatment studies.As a result,though less
than a decade old,early intervention and prevention stud-
ies have now spread throughout the world.
34,35
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Selected abbreviations and acronyms
AD antidepressant
AP antipsychotic
CBT cognitive behavioral therapy
CHR clinical high risk
NBI needs-based intervention
PACE Personal Assessment and Crisis Evaluation 
(program) 
PRIME Prevention through Risk Identification,
Management,and Education (program)
RAP Recognition and Prevention (program)
SGAP second-generation antipsychotic
SLP schizophrenia-like psychosis
SPI specific preventive interventionWhat should be treated?
The issue of what should be treated is highly complex at
this stage of research.Since the field is young and con-
tinues to evolve,the natural course of the prodrome is
not well established and the population continues to be
“at risk”rather than to consist of affected patients with
a definite syndrome.
6,35 As a result, there is some dis-
agreement throughout the field as to what symptoms to
treat,and what the short- and long-term treatment goals
should be.Rates of conversion to psychosis among pro-
dromal individuals range from 20% to 45%,depending
on how the prodrome is defined and measured.
36-38This
complicates interpretation of treatment findings and
raises the question as to whether emphasis should be
directed to prevention (ie,lowering the incidence rates)
or reducing functional disability,often present in at-risk
individuals regardless of whether psychosis has emerged.
Thus far, treatment has primarily targeted attenuated
positive symptoms that occur relatively late in the pro-
drome.Only a minimum of attention has been directed
toward treatment of earlier,negative symptoms,identi-
fied by previous high-risk and follow-back studies
15-19 to
be the earliest risk factors of illness.This is an important
oversight, since these early deficits appear to be most
closely associated with the functional disability (ie,inabil-
ity to work independently,social isolation) that is thought
to restrict prognosis more directly than psychosis, in
itself.
39,40 Thus, a major research goal, at present not
widely recognized,should be to determine whether neg-
ative risk factors and deficits can be reduced with early
treatment, and, if doing so has in turn the potential to
improve functional outcome.
Because of the many unresolved issues characterizing the
treatment of the prodromal phase,the questions asked
tend to vary widely from site to site.Although the poten-
tial for answers is considerable,there are few definitive
findings available,
41 and the data that do exist are quite
variable.Falloon
42 conducted the first attempt at preven-
tion using AP medication in a study in rural Britain.In
this project,family practitioners were educated to iden-
tify prodromal individuals using Diagnostic and Statistical
Manual of Mental Disorders, Third Edition, Revised
(DSM-III-R) prodromal criteria and to refer these
patients to a multidisciplinary early intervention team.
Sixteen individuals meeting entry criteria were provided
intensive stress management and family psychosocial
intervention and were treated with low-dose neuroleptic
medication when necessary.The results of these efforts
suggested that early intervention reduced conversion
rates (compared to those previously recorded in the
catchment area),although these findings were not con-
sidered to be conclusive because the study was conducted
under uncontrolled conditions.
Following Falloon,prodromal programs were established
in Melbourne,Australia (Personal Assessment and Crisis
Evaluation [PACE] clinic),
37,43 and in the USA in
Connecticut (Prevention through Risk Identification,
Management,and Education [PRIME] clinic)
44 and New
York (Recognition and Prevention [RAP] program).
4-6
At present,findings are thus far largely limited to these
three original prodromal programs.Although there are
some commonalities,each of these programs has adopted
different research and treatment strategies.For example,
both the McGorry and McGlashan treatment groups
(PACE and PRIME clinics) focus on randomized clinic
trials. Starting from a very different perspective,
Cornblatt et al (RAP program) report findings from a
prospective naturalistic study, which is as much con-
cerned with defining risk factors as with treatment.Each
of these programs will be described separately.
PACE clinic randomized clinical trial
Researchers in the PACE clinic,
45,46 which is part of the
Early Psychosis Prevention and Intervention Center
(EPPIC) program
43 in Melbourne, Australia, were the
first group to focus on the schizophrenia prodrome in a
series of systematic,controlled studies.As a result,this
group has conducted much of the groundbreaking con-
ceptual and early research that jump-started the field.
Although new trials are underway in the PACE clinic,to
date,the major treatment findings have resulted from the
original randomized clinical trial (RCT)
47 in which a
study group receiving low-dose risperidone combined
with cognitive behavioral therapy (CBT) was compared
with a “needs-based”treatment control group.This was
the first randomized,controlled intervention trial con-
ducted in prodromal individuals.
Patients were between 14 and 30 years and met any one
or more of three criteria, considered to define “ultra
high-risk”(UHR):
• Attenuated psychotic symptoms defined as subthresh-
old attenuated positive symptoms that do not reach
psychotic intensity yet represent distinct departures
from normal experience.
Treating early psychosis - Cornblatt and Auther Dialogues in Clinical Neuroscience - Vol 7 . No.1 . 2005
41• Brief limited intermittent psychotic symptoms (BLIPS),
defined as the presence of infrequent or intermittent
psychotic level symptoms of a duration <1 week,that
spontaneously remit.
• Trait and state risk factors defined as the presence of
psychosis or schizotypal personality disorder in a first-
degree relative or schizotypal personality disorder in
the identified patient, and a decrease in functioning
that is sustained for 1 month.
Conversion to psychosis, the outcome of interest, is
defined as meeting the criteria for a brief limited psy-
chosis for longer than 1 week.
The trial compared a needs-based intervention (NBI,the
control condition) with a specific preventive intervention
(SPI).The NBI consisted of a focused supportive psy-
chosocial intervention. The SPI combined 1 to 2 mg
risperidone with a modified CBT program,in addition to
focused supportive intervention.Interventions were pro-
vided for 6 months,after which patients in both groups
received 6 months of NBI.Treatment was augmented
with antidepressants (ADs) and benzodiazepines when
necessary in both groups.
Fifty-nine high-risk subjects were randomized and some
differences were found between the groups in terms of
use of ADs (NBI>SPI) and number of therapy sessions
received (SPI>NBI).At 6 months,the rate of conversion
to psychotic illness (not necessarily schizophrenia) was
significantly higher in the control (NBI) group (36%,
10/28) than the early intervention (SPI) group (10%,
3/31). However, this difference did not hold up at the 
1-year mark (36% NBI versus 19% SPI).
If adherence to medication was considered,those who
were fully compliant with the intervention procedures in
the SPI group were significantly less likely to convert
than those in the NBI group at both 6 and 12 months.
However,these findings are not conclusive since more
than half of the subjects in the SPI group were less than
fully compliant with medication.All participants showed
symptom improvement across the study,including con-
verters (who received treatment immediately, a major
advantage of participating in the study) and few adverse
effects were reported. However, functional levels
remained relatively unchanged,which may indicate that
more intensive or longer duration of intervention is
needed to elevate global functioning.These findings sug-
gest that short-term treatment can delay psychosis.The
authors conclude that the number needed to treat (NNT)
of four (ie,four individuals would need to be treated in
order to prevent conversion in one) supports continued
prodromal trial research.More clarity is expected from
a 12-month,randomized,controlled trial initiated in the
PACE clinic in 2000,in which risperidone plus CBT will
be compared with placebo plus CBT,and with placebo
plus befriending.
PRIME clinic randomized double-blind study
McGlashan et al
44 at Yale initiated the first double-blind,
placebo trial for prodromal patients in 1997.After addi-
tional sites were added,60 subjects were enrolled in the
project with 30 randomized to receive olanzapine (5 to
15 mg) and 29 to receive placebo.Medication or placebo
was given for 1 year and patients were followed for an
additional year. Inclusion criteria were based on the
Yung UHR categories, but operationalized by the
PRIME prodromal assessment tool, the Scale of
Prodromal Symptoms (SOPS).
48,49 Conversion to psy-
chosis,defined by this group as any positive symptom at
psychotic intensity on SOPS that was of sufficient fre-
quency,duration,or was seriously disorganizing or dan-
gerous,warranted removal from the trial and open-label
olanzapine was initiated for 6 months.Supportive psy-
chosocial interventions were available for all patients,but
effort was made to limit the use of concomitant psy-
choactive medications. Results analyzed by principal
mixed-effects model after 8 weeks of treatment revealed
that the olanzapine group showed significant improve-
ment from baseline on SOPS total score,positive symp-
tom scale, negative symptom scale, and disorganized
symptom scale.The placebo group did not show any sig-
nificant change on any scale at any time point.
Olanzapine versus placebo group differences were found
by week 8 on the SOPS total,negative,and disorganized
scales,but not the positive symptom scale.Positive and
Negative Symptoms Scale (PANSS) total and positive
symptom scores also showed significant differences
between the olanzapine and placebo groups.Weight gain
was the only side effect reported significantly more often
in the olanzapine group, with over 50% of this group
gaining more than 7% of their baseline body weight (ver-
sus 3% in placebo group).
36 Patients receiving olanzap-
ine showed significant within-group improvements on
positive symptom scores and a trend toward greater
improvement when compared to the placebo group,
demonstrating the efficacy of olanzapine over placebo in
the treatment of attenuated positive symptoms.Although
Pharmacological aspects
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conversion rates in the placebo group (34%,10/29) were
higher that those in the olanzapine group (16%, 5/31)
after 1 year of active treatment,this difference did not
reach statistical significance.
50Thus,while results of both
the PACE and PRIME studies support the short-term
benefits of early treatment,prevention continues to be
an open question.
41
RAP program naturalistic prospective study
A very different approach has been adopted in the RAP
program.Prior to any type of formal treatment trial,the
RAP program has been designed to collect data about
the longitudinal progression of symptoms and function-
ing within a naturalistic treatment framework. In this
context,psychosocial and pharmacological interventions
are provided according to the physician’s choice,based
on best practice guidelines.This strategy thus provides
real world treatment information, which is currently
unavailable, especially naturalistic conversion rates. It
also provides an initial evidence base to inform the
design of treatment trials.Considered as a high-risk study,
initial RAP goals are to identify the critical risk factors
defining the prodrome;longer-term goals are to evaluate
the changes in these deficits associated with treatment.
A critical component of the RAP program approach is
to cast a wide net to identify patients in various stages of
the prodrome.Selection criteria are directly derived from
our neurodevelopmental model,which has evolved over
several years.The resulting working diagnostic model is
presented in Figure 1.
In the diagnostic schema in Figure 1,the term “clinical high
risk”(CHR) is substituted for “prodromal”;sample sizes
shown in each of the boxes are current as of 1 July 2004.
Stage 1 of this diagnostic schema consists primarily of neg-
ative-type symptoms (eg,increasing social isolation,school
failure,depression) and is referred to as CHR-negative or
CHR-.The CHR- stage is followed by the gradual emer-
gence of positive symptoms,which first appear in mild-to-
moderate attenuated form (CHR+mod;stage 2),and then
increase in severity (CHR+sev;stage 3),although still not
of psychotic intensity.In many cases,these positive symp-
toms evolve into psychosis,though not necessarily meet-
ing criteria for schizophrenia.Presence of only one posi-
tive symptom of psychotic intensity is considered stage 4
in the model and is referred to as schizophrenia-like psy-
chosis (or SLP). The sequence is therefore CHR- →
CHR+mod → CHR+sev → SLP. The end point of this
process is proposed,in many,though not all,cases to be
full-blown schizophrenia.This model is designed to focus
on the course of development,a process that is not yet well
understood.
51 Aside from providing a number of entry
points into the prodrome,this model also provides a struc-
ture for developing and evaluating stage-specific inter-
ventions. For example, early treatment data, to be dis-
cussed in later sections,suggest that,for the early stages of
the prodrome, ADs are associated with a much higher
level of adherence in adolescents and appear equally as
effective for symptom control as APs.Thus,our focus is on
identifying the optimal intervention during each prodro-
mal stage.
Data from the RAP program concur with the McGorry
and McGlashan groups in that our prodromal population
is treatment-seeking,highly symptomatic at baseline,and
generally benefits from intervention.
52 Overall,the con-
version rate within the RAP program across subjects
with follow-up of at least 6 months is 20%. Consistent
with our recruitment strategy and focus on the very early
stages of the prodrome,our conversion rate is at the low
end of the spectrum. However, when looked at more
closely as a function of the RAP theoretical model,the
pattern of clinical deterioration for the 97 subjects who,
to date,have been followed for at least 1 year (mean fol-
low-up 2.4 years) is highly consistent with our develop-
mentally based expectations.These results are presented
in Figure 2.
Within each box are included those subjects who
received that classification (ie,CHR-,CHR+mod,etc) at
Figure 1. Expanded four box model. CHR-: clinical high risk–negative; CHR+mod: clinical high risk–positive moderate; CHR+sev: clinical high risk–
positive severe; SLP: schizophrenia-like psychosis.
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study entry and who also have at least 1 year of follow-
up.Arrows represent outcome as of a 1 June 2004 cutoff
date,though only the final outcome is represented (ie,
intermediate shifts not shown).This preliminary longitu-
dinal data provide some very early support for our devel-
opmental model indicating that rates of conversion will
increase as subjects progress across prodromal stages
from CHR- to SLP.This figure also presents the rates of
broadly defined clinical deterioration from any given
prodromal stage to a more severe one.As indicated by
the figure, frequency of clinical deterioration shows a
gradual increase from CHR- (14%) to CHR+mod (22%)
to CHR+sev (30%) to SLP (50%).
Naturalistic findings indicate that early treatment may be
more complex than typically assumed,in that APs are not
necessarily first-line choice in best-standards practice.For
those participants in the CHR+ category (which are com-
parable to the prodromal groups treated by both the
McGorry and McGlashan groups), psychiatrists in the
RAP program prescribed AD medication as often as AP
medication.Furthermore,those on ADs generally did as
well as those on APs (all SGAPs).
52This finding has led to
initiation of a 16-week,double-blind,double-dummy study
of an SGAP (risperidone) versus a typically used AD (ser-
traline),which is currently underway.Goals of the project
are to determine the efficacy of the two classes of med-
ication on symptom reduction and to determine if there is
a differential rate of conversion between the groups.
Conversion in the study will reflect psychotic symptoms at
a high enough frequency and duration to meet Diagnostic
and Statistical Manual of Mental Disorders,Fourth Edition
(DSM-IV) criteria for a specific psychotic disorder (eg,
schizophrenia,schizoaffective,or delusional disorder).
Treating functional disability
Preventing conversion to psychosis is the primary goal of
early intervention.However,given the current fluctua-
tion in conversion rates and the small number of subjects
who convert in any given study,the collection of conclu-
sive data indicating the success of current interventions
using AP medication is a long-term goal and may require
several multisite studies.
53 Conversion rates can vary dra-
matically even within a single site.Yung et al,
37 for exam-
ple,reported a conversion rate of 21% (7/33) after an ini-
tial 12 months of follow-up,but then,in another sample
with refined inclusion criteria,found a 40.8% (20/49) con-
version rate at 12 months’ follow-up,with 28.5% of the
sample converting to schizophrenia or schizoaffective
disorder and the balance converting to affective psy-
Figure 2. Preliminary outcome. Within each box are included those subjects who received that classification at study entry and who also have 1 year of
follow-up. Arrows represent outcome as of a 1 June 2004 cutoff date. CHR-: clinical high risk–negative; CHR+mod: clinical high risk–positive
moderate; CHR+sev: clinical high risk–positive severe; SLP: schizophrenia-like psychosis.
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choses or brief/unspecified psychosis.Differences in rates
are also dependent on how the end point is defined.For
example,in the PACE study,outcome is psychosis;in the
RAP program, the outcome is schizophrenia, and psy-
chosis is considered to be an intermediate state (repre-
sented by the SLP group) with an unclear final outcome.
A second,very important direction,however,is the treat-
ment of risk factors and the long-term functional out-
come they are associated with;this is a major component
of the naturalistic research design of the RAP program.
Early risk factors include subtle deficits in cognition,
social skills,and school performance,which have been
shown both in affected patients and in youngsters at risk
to lead to social isolation and poor vocational skills in
adulthood.
39,40,52,54,55According to our theoretical neuro-
developmental model,such core risk factors reflect a vul-
nerability to later illness and are thought to be early,sta-
ble manifestations of underlying brain abnormalities.
Early risk factors are of particular interest in an inter-
vention context to the extent that they can be modified
by treatment.Our basic hypothesis is that the early treat-
ment of such risk factors will impact the progression of
illness and hopefully prevent (or,at least greatly reduce)
psychosis and functional disability.
In the RAP program,we have thus far focused on four
possible core domains,which appear to be early risk fac-
tors:cognitive deficits,affective disturbances,social iso-
lation,and school functioning (referred to in our program
as the CASIS cluster).In particular,social deficits and
impaired school functioning are the symptoms most com-
monly reported across patient subgroups, with one or
both reported by 94% of all prodromal subjects.In addi-
tion, these early childhood/adolescent deficits are
thought to be directly related to the social and vocational
deficits characteristic of many adults affected with schiz-
ophrenia.
Functional outcome domains have not yet received sig-
nificant attention in the prodromal literature,which has
focused almost exclusively on prevention of psychosis
and related clinical symptomatology, as discussed
above.
47,56,57 However, longitudinal studies of affected
patients with schizophrenia have repeatedly demon-
strated that the long-term course of illness is marked by
persistent impairment in community functioning,even
when psychotic symptomatology is in remission.
58-61 Of
further significance, functional impairments, including
cognitive,social and occupational/academic deficits are
independent of psychotic symptoms.A major goal of the
RAP program is to determine the extent to which early
intervention will have an impact on these long-standing
core deficits,thus improving long-term outcome.
Focus in the RAP program,therefore,has been increas-
ingly directed to areas of functional outcome in addition
to conversion to psychosis.Functional disability is both
widespread in the prodromal population and very diffi-
cult to treat at present.Two areas of outcome are studied
in depth:social isolation and deteriorating role function-
ing,which,in adolescents,refers to school performance.
Preliminary outcome data indicate that social function-
ing is highly stable over time, whereas school perfor-
mance appears to be more variable.Both of these areas
are currently viewed as primary treatment targets in our
program.
When to treat and what to treat with
At present,the prodrome is regarded as a unitary clini-
cal entity by most researchers.The assumption that fol-
lows is that all patients meeting prodromal criteria should
be treated at presentation using the same medication,ie,
SGAPs.This choice results from at least two considera-
tions:first,from the assumption that since APs are the
best known way of treating affected psychotic patients,
they will also be the best way to prevent psychosis from
starting in the first place.Second,movement disorders
such as tardive dyskinesia no longer appear to be as
severe with SGAPs as with the preceding neuroleptics,
thus reducing ethical issues involved in treating prepsy-
chotic,at-risk individuals.
62APs are especially appropri-
ate in studies that limit entry criteria to prodromal symp-
toms conceptually very close to onset of psychosis.As a
result,the majority of the individuals in these samples are
likely to be in the late prodromal stage and may not be
representative of the prodromal period in general.
Early findings emerging from the RAP program have
challenged several of the above assumptions to varying
extents.First,as indicated by the developmental pattern
of clinical deterioration shown above in Figure 2,the pro-
drome appears to consist of multiple stages, each of
which may involve a different type of treatment.The pat-
tern of deterioration shown preliminarily suggests that,
rather than later in the prodrome,it might be more effec-
tive for intervention to begin in the CHR+mod stage,
when symptoms are less severe and possibly more
responsive to treatment.In addition,these early clinical
findings suggest the importance of initiating some typeof treatment at the CHR- stage,although this is likely to
be psychosocial rather than pharmacological.
Following this model,the prodromal phase might be more
broadly conceptualized as having an early period and a
late period,each with different treatment requirements.In
the early prodromal phase,affective symptoms and neg-
ative attenuated signs are beginning to emerge and to have
some impact on age-dependent functioning.For example,
in a large-scale retrospective study of prodromal schizo-
phrenia conducted by Hafner and an der Heiden,
63 depres-
sion and nonspecific symptoms including impairment in
social functioning were evident up to 5 years before the
onset of positive symptoms.These findings are mirrored in
follow-back studies
7,64,65 and genetic high-risk studies.
16,54,66
Furthermore,level of social/role functioning attained by
onset of psychosis mediated social consequences 5 years
later, indicating that successful intervention in the pro-
dromal period could prevent developmental arrest in
these areas.
67 Medications other than APs may be most
useful in treating these early phase deficits and behavioral
problems.By contrast,the late prodromal phase is char-
acterized by the development of attenuated positive symp-
toms that are the harbingers of psychosis.Retrospective
reports indicate that although the early prodromal period
of largely negative-type symptoms might last from weeks
to years,
28,68 there is a typically steep decline in the 6-month
to 1-year period prior to onset.
44 This suggests that APs
might best be administered at the point of evident decline,
as suggested by McGlashan and colleagues.
44,69
Preliminary treatment findings from the RAP program
support this developmental treatment perspective.The
naturalistic treatment strategy of the RAP clinic, the
independent treatment arm of the RAP program,
involves the following: (i) treating clinicians are inde-
pendent of the prodromal study research team;(ii) there
are no research guidelines as to treatment;(iii) clinicians
are asked to prescribe medication as they would in their
private practice,ie,based on best practice guidelines for
treatment of symptoms;and (iv) prevention is not taken
into consideration.This has generated a rich database of
observed treatment data.
The naturalistic treatment data collected over the early
years of the RAP program has generated a consistent
finding that has been repeated as the prodromal sample
has continued to grow. As has been reported several
times for patients with attenuated positive symptoms (eg,
CHR+)
4,5 on small,but increasing samples (with the most
recent n=39),the major results are as follows:
• Most adolescents with prodromal symptoms are
treated with either SGAPs, with ADs (involving a
range of selective serotonin reuptake inhibitors
[SSRIs]),or with both.
•There are no baseline differences in severity of either
positive,negative,or depressive symptoms to account
for the choice.
• Prodromal youngsters treated with ADs do at least as
well as those treated with SGAPs over about a 2-year
follow-up period.
•There is no difference in baseline symptoms,adherence,
or outcome between adolescents receiving a combina-
tion of SGAP/AD vs SGAPs alone,thus questioning
the need for polypharmacy.
• Nonadherence to medication appears to be the single
most important factor determining conversion to psy-
chosis.Of the 13 prodromal adolescents who converted
to psychosis over follow-up, 12 were nonadherent to
medication (defined as off medication for 1 month or
longer),which,in all cases,was an AP.Nonadherence
thus confounds outcome,but suggests that ADs may be
an option,since they appear effective clinically and,in
comparison with APs, the rate of adherence is very
high.
Although in no way conclusive,since naturalistic data are
based on nonrandom assignment and are open-label,our
initial findings raise several issues. Important among
these is the issue of whether APs should be the first-line
treatment choice for all prodromal individuals.At pre-
sent, other possibilities are being explored both in the
RAP program and in the other two prodromal programs
(ie,PACE and PRIME).
How long to treat?
There are currently no direct data to support how long
treatment will be necessary,either for prevention of psy-
chosis or to reduce functional disability. Previous stud-
ies typically lasted from 1 to 2 years.Additional infor-
mation is also needed to guide researchers in optimal
treatment trial duration.To date, treatment trials have
been of relatively short duration, generally 6 to 12
months of active treatment with a year or two of follow-
up.How long treatment should be provided is unknown
at present.The results of the PRIME trial seem to indi-
cate that symptom improvement is related to being
actively medicated and,when medication is withdrawn,
symptoms reemerge.
70 Perhaps the duration of treatment
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46was not long enough to change the course of the illness.
In the RAP program,which,as discussed above,includes
early stages of the prodrome, at least 35% of the con-
versions occurred during years 3 to 4 of the study.
Moreover, all but one of the subjects in the RAP pro-
gram who converted had been off medication for sub-
stantial periods of time.Risk for conversion was greatly
increased by nonadherence.This suggests that sustained
medication may be essential to stave off onset of psy-
chosis.This finding in prodromal youngsters is consistent
with the findings reported for first-episode patients,with
risk for relapse increased fivefold when nonadherent
with medication.
31
Future directions
Now a decade into the early intervention work,there has
been increased interest in broadening the focus to
include interventions that target more than just positive
symptoms, and include negative symptoms and func-
tional disability.It is clear that more information on the
developmental course of the prodrome is needed to iden-
tify treatment targets.Several groups have begun to char-
acterize the early versus late prodromal period.
52,71 For
example,a treatment trial underway in Germany has ran-
domized early-phase prodromal participants to receive a
program of CBT or clinical management and random-
ized late-stage prodromal participants to clinical man-
agement alone or in conjunction with AP medication.
71
Results from such studies will contribute to our under-
standing of when treatment should be most profitably
initiated,what type of treatment is most appropriate for
each prodromal phase,and the criteria most helpful in
evaluating short-term treatment effects.This shift in focus
may bring about novel interventions such as the use of
newly marketed SGAPs, ADs, cognitive enhancers,
glycine,d-cycloserine,hormones,and psychosocial inter-
ventions that target specific skill deficits (eg,social skills
group).
In addition,a collaborative effort under the leadership of
Heinssen involving several prodromal research groups in
the USA and Canada (Principal Investigators:Addington,
Cadenhead, Cannon, Cornblatt, McGlashan, Perkins,
Seidman,Tsuang,Walker,and Woods),referred to as the
North American Prodromal Longitudinal Study (NAPLS),
has been recently formed to provide a common database
with a large prodromal sample. This collaboration is
expected to increase consistency between studies by devel-
oping common methodologies, common measurement
instruments,and correspondence between definitions of
conversion. Several other networks have been initiated
throughout Europe,including the European Prediction of
Psychosis Study (EPOS) in Finland,led by Salokangas,and
the Swiss Consortium currently headed by Simon. Such
collaborations offer the hope that large databases will
result, each with far more subjects and statistical power
than possible for any study alone.Conclusions have thus
far been elusive given the rarity of the prodromal state and
the difficulty in ascertaining a substantial prodromal pop-
ulation. Large-scale collaborations offer the promise of
generating a solid set of generalizable conclusions about
the prodrome,which are reliable,valid,and representative
of a broad preschizophrenia population.
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El tratamiento de la psicosis precoz: 
¿a quiénes, con qué y cuándo?
La intervención precoz y la prevención de la esqui-
zofrenia no tienen más de diez años. El supuesto
que guía estas acciones alude a que la intervención
resulta probablemente más efectiva si comienza
previo a la instalación de la psicosis, es decir,
durante la fase prodrómica. Aunque en diversas
partes del  mundo se han iniciado un número sig-
nificativo de programas de tratamiento prodró-
mico, tres de ellos –hasta la fecha– han dado origen
a la mayoría de los hallazgos de esta intervención:
el Personal Assessment and Crisis Evaluation (PACE)
en Australia, y los programas Prevention through
Risk Identification, Management and Education
(PRIME) y Recognition and Prevention (RAP) en
Estados Unidos. Los resultados sugieren que la
intervención precoz lleva a una reducción de los sín-
tomas prodrómicos y del distrés clínico. Sin
embargo, la prevención de la psicosis persiste como
una pregunta sin resolver. Otro aspecto de esta revi-
sión es la definición de quiénes deben ser tratados,
con qué y cuándo. Además, continúan apareciendo
objetivos terapéuticos que se asocian con incapaci-
dad funcional como son los síntomas negativos pro-
drómicos precoces y los factores de riesgo. A su vez,
síntomas blanco identificados recientemente sugie-
ren la necesidad de una variedad de nuevas inter-
venciones y estrategias terapéuticas.
Traiter précocement une psychose : 
qui, avec quoi et quand ?
La notion d’intervention précoce et de prévention
dans la schizophrénie vient juste de dépasser 10
ans. L’hypothèse sous-tendant cette réflexion est
probablement d’être plus efficace si l’on intervient
avant l’installation de la psychose, par exemple,
pendant la phase prodomique. Bien que de nom-
breux programmes de traitements prodromiques
aient été débutés dans le monde entier, à ce jour,
trois programmes d’intervention précoce sont à
l’origine de la plupart des résultats : PACE (Personal
Assessment and Crisis Evaluation) en Australie,
PRIME (Prevention through Risk Identification,
Management and Education) et RAP (Recognition
and Prevention) aux États-Unis. Les données sug-
gèrent qu’une intervention précoce réduit les symp-
tômes prodromiques et la souffrance clinique.
Néanmoins, la prévention de la psychose demeure
un problème non résolu. D’autres questions restent
en suspens comme, qui devrait être traité ? avec
quoi et quand ? De plus, les traitements ciblant l’in-
capacité fonctionnelle, comme les symptômes néga-
tifs prodromiques précoces et les facteurs de risque,
continuent à apparaître. Des cibles nouvellement
identifiées font ressentir à leur tour le besoin de
diverses nouvelles interventions et stratégies thé-
rapeutiques.Treating early psychosis - Cornblatt and Auther Dialogues in Clinical Neuroscience - Vol 7 . No.1 . 2005
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